上海昊海生物科技(06826.HK) 就早前公布的收购江西瑞济生物工程技术股份有限公司(“江西瑞济”)的股权交易,发出补充公告,进一步解释收购价如何厘定,以及目标公司的实际控制资讯,并重申目标股份的每股价格属公平合理,且符合公司及其股东整体利益。上海昊海指出,江西瑞济的股权收购价为每股4.53元人民币(下同),价格综合考虑目标公司去年2月11日最后交易日的收盘价(每股4.81元)及此前的股份回购...
Source Link上海昊海生物科技(06826.HK) 就早前公布的收购江西瑞济生物工程技术股份有限公司(“江西瑞济”)的股权交易,发出补充公告,进一步解释收购价如何厘定,以及目标公司的实际控制资讯,并重申目标股份的每股价格属公平合理,且符合公司及其股东整体利益。上海昊海指出,江西瑞济的股权收购价为每股4.53元人民币(下同),价格综合考虑目标公司去年2月11日最后交易日的收盘价(每股4.81元)及此前的股份回购...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.